Atlas
Market PulseMovers & ShakersSector ViewStocksETFFundsPortfoliosAdmin
Atlas › Stocks › UNICHEMLAB

UNICHEMLAB

Unichem Laboratories Limited
Micro-capPharma ↗

What the six lenses say about UNICHEMLAB — its relative strength vs the baselines, price & RS trend, the 8-quarter financials, and live filings.

Price
₹569.8
2026-09-08
VWAP · 1Y anchor
₹487
+16.9% from VWAP
P/E · TTM
15.9×
TTM EPS ₹35.9
52-week range
78%
position low→high
RSI(14)
61
momentum

Own sector index

Pharma ↗
Overweight

1M

+0.4%

3M

+10.5%

1Y

+22.0%

Breadth >EMA21

56%

How UNICHEMLAB’s own sector index is moving — context for reading the stock’s six lenses.

Six-lens read

What the six lenses say

How the lenses are scored ↗
Strength
10.0
avg conviction decile
Leadership
Leader
top-decile composite in cohort
Each lens is a decile within its cap cohort (D10 = top 10%) — no black-box composite. Expand a lens for the real numbers behind it.
LensDecile · Micro-cap cohortDRaw
TechnicalD10100›

The actual numbers

Price vs VWAP (1y)+16.9%
EMA trend stackUp · 21>50>200
Price vs 200-EMA+21.8%
Price vs 50-EMA+9.9%
RSI(14)61
RS vs Nifty 500 · 3M+55.2%
RS vs sector · 3M+49.2%
52-week range78%
Volume vs 30d avg0.28×
Volume vs 60d avg0.07×
ATR(14) · volatility31.9
Bollinger width · vol contraction0.135
FundamentalD751›

The actual numbers

Return on equity (ROE)9.3%
Operating margin14.7%
Net margin11.5%
Revenue growth · YoY+8.5%
EPS growth · YoY+67.9%
Debt / equity0.18×

Full 8-quarter history in the financials table below.

ValuationD749›

The actual numbers

P/E (TTM)15.9×
TTM EPS₹35.9
52-week range78%
CatalystD223›

The actual numbers

Earnings & momentum12
Capital actions27
Governance55

Every filing in the corporate-announcements panel below.

FlowD1062›

The actual numbers

Promoter holding70.2%
Delivery · 30d avg38.7%
Up/down-day asymmetry-6.8pp
How the decile & conviction are calculated

Decile — each lens’s 0–100 score is ranked against every Micro-cap stock in the universe. D10 = top 10% (strongest), D1 = bottom 10%. A decile is simply where this stock sits versus its size-peers on that lens — no weighting, no black box.

Conviction — the average of the two active conviction-lens deciles (Technical & Flow):

( D10 + D10 ) ÷ 2 = 10.0(Technical · Flow)

Fundamental, Catalyst, Valuation and Policy are shown for context but carry weight 0 in the current model, so they are not scored into conviction. Full detail on the methodology page ↗.

Glass box

How the score is built

Click a lens to expand its sub-components, then drill to the actual values. The eye icon on any term explains it.

Conviction score · Highest
96
Conviction score 96/100 · avg-decile strength 10.0/10
Conviction score96/100›
TechnicalD10›
FundamentalD7›
ValuationD7›
CatalystD2›
FlowD10›

Policy

Government policy · Pharma

Active policies relevant to this sector — flagged as a Red / Amber / Green signal, not scored into the six-lens conviction. The lenses say what the market is doing; policy is context for why.

Tailwind· HIGH impact

PLI Scheme — Pharmaceuticals & API

Production-linked incentive scheme for pharmaceuticals, APIs, and medical devices

Relative strength · always on

Percentage-point spread vs each baseline across six windows. Green = outperforming, red = lagging. Data as of 2026-09-08.

Baseline1D1W1M3M6M12M
Nifty 50
Large-cap anchor
+4.0pp
+3.6pp
+18.0pp
+56.8pp
+79.5pp
+16.6pp
Nifty 500
Broad-market baseline
+4.0pp
+3.6pp
+17.0pp
+55.2pp
+73.7pp
+11.4pp
Sector
Own-sector index
—
—
+14.1pp
+49.2pp
+60.6pp
-9.4pp

From atlas_foundation.technical_daily. Sector row covers 1M–12M (1D/1W not stored).

Trend

Price · EMA 20 / 50 / 200

UNICHEMLAB daily close with the three trend EMAs · atlas_foundation.ohlcv_stock.

₹ (close)
569.75+19.55

Relative strength

RS vs baseline · rebased to 100

UNICHEMLAB ÷ Nifty 500, rebased to 100 at window start — above 100 = outperforming since then.

RS vs Nifty 500 (=100)
102.08+3.92

TradingView composite technical analysis — multi-timeframe consensus

Quarterly financials

Last 8 quarters from the company’s filings (₹ crore) — revenue, profit, margins and the growth trend.

MetricJun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue (₹cr)446462533587527579521575
↳ change QoQ—+3.5%+15.3%+10.1%-10.2%+9.9%-10.0%+10.4%
EBITDA (₹cr)4766998422664548
EBITDA margin10.6%14.3%18.6%14.3%4.2%11.4%8.6%8.3%
PAT (₹cr)9305853-10-1226411
↳ change QoQ—+229.4%+89.7%-8.4%-118.9%-20.0%+2300.0%-95.8%
Net margin2.1%6.6%10.8%9.0%-1.9%-2.1%50.7%1.9%
EPS (₹)1.314.348.227.52-1.49-1.6937.541.55
D/E————————
YoY growth · Mar '26Revenue -2.0% YoYPAT -79.2% YoY

Corporate announcements

Filings to the exchange — capital actions, earnings and governance. Most recent first.

  • 26 Aug '26
    LOWgovernance
    Spurt in Volume
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 25 Aug '26
    LOWgovernance
    Spurt in Volume
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 Aug '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 29 Jul '26
    LOWgovernance
    Action(s) initiated or orders passed
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 14 Jul '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Jul '26
    LOWgovernance
    Price movement
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Jul '26
    LOWgovernance
    Price movement
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 6 Jul '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 3 Jul '26
    LOWgovernance
    Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 11 Jun '26
    LOWgovernance
    Spurt in Volume
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 10 Jun '26
    LOWgovernance
    Spurt in Volume
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 1 Jun '26
    LOWgovernance
    General Updates
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 22 May '26
    HIGHearnings
    Outcome of Board Meeting
    ›

    An exchange filing — open the original disclosure on NSE for the full text.

    View original filing on NSE ↗
  • 20 Apr '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗
  • 13 Apr '26
    MEDIUMgovernance
    Disclosure under SEBI Takeover Regulations
    ›

    A governance / disclosure filing — lower signal weight, context only.

    View original filing on NSE ↗

…and 5 more.

Ownership

Who holds UNICHEMLAB

Mutual funds holding UNICHEMLAB (2)

FundWeightAUM ₹crGrade
HDFC Small Cap Gr0.61%41,679
DSP Healthcare Fund Reg Gr1.59%3,639

ETFs holding UNICHEMLAB (0)

No tracked ETF holds UNICHEMLAB ≥0.5%.

Show company profile (about, sector, employees, IPO)
Native from atlas_foundation — lens journal, technical_daily, ohlcv_stock; TradingView for the live instrument view. ← Back to Pharma